Trial Profile

A Phase II Study of Olaparib and Durvalumab (MEDI 4736) in Patients With IDH-Mutated Solid Tumors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Olaparib (Primary)
Indications Adenocarcinoma; Astrocytoma; Biliary cancer; Brain metastases; Cholangiocarcinoma; Glioblastoma; Glioma; Oligodendroglioma; Solid tumours
Focus Therapeutic Use
Acronyms SOLID

Most Recent Events

30 Apr 2025 Results assessing cfDNA methylome as a non-invasive biomarker of response, presented at the 116th Annual Meeting of the American Association for Cancer Research.
18 Jul 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2025.
04 Jun 2024 Results (n=29) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com